Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Earnings per Share (Diluted) : $-0.97 (TTM As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Earnings per Share (Diluted)?

Cancer Prevention Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2016 was $-0.44. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 was $-0.97.

Cancer Prevention Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2016 was $-0.44. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2016 was $-0.97.

Cancer Prevention Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2016 was $-0.60. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2016 was $-1.40.

Cancer Prevention Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Earnings per Share (Diluted) Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Earnings per Share (Diluted)

-1.37

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Earnings per Share (Diluted)	Get a 7-Day Free Trial			-	-	-	-0.53	-0.44

Competitive Comparison of Cancer Prevention Pharmaceuticals's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Prevention Pharmaceuticals's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's PE Ratio falls into.

Cancer Prevention Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Cancer Prevention Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2015 is calculated as

Diluted Earnings Per Share (A: Dec. 2015 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-5.681	-	0)	/	3.468
	=	-1.64

Cancer Prevention Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2016 is calculated as

Diluted Earnings Per Share (Q: Mar. 2016 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-3.323	-	0)	/	5.495
	=	-0.60

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.97

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Cancer Prevention Pharmaceuticals (AMEX:CPP) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cancer Prevention Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.